Latest Research And Development News

Ainsworth Game Technology reported a steady half-year profit of $4.9 million on a 25% revenue increase, driven by strong domestic sales and new product launches, while navigating regional challenges and a looming Novomatic takeover bid.

VEEM Limited has achieved approved supplier status with Huntington Ingalls Newport News Shipbuilding, positioning itself to enter the US defence supply chain with anticipated RFQs in the first half of FY26.

Etherstack plc has delivered a record half year performance in H1 2025, driven by a landmark multi-year contract with AT&T and surging recurring revenues. The wireless communications specialist is poised for sustained growth across its core markets.

Etherstack plc has reported a remarkable turnaround in its half-year results, with revenue nearly doubling and EBITDA surging by over 1500%, signaling strong momentum in mission critical communications.

Hansen Technologies reported robust FY25 results, driven by strong growth in its Energy & Utilities and Communications & Media sectors, highlighted by a major $50 million contract with VMO2. The company’s disciplined cost management and strategic investments in AI and acquisitions underpin its optimistic outlook for FY26.

Breville Group Limited reported robust FY25 results with double-digit revenue and profit growth, successfully navigating US-China tariff challenges through strategic manufacturing diversification and market expansion.

Ainsworth Game Technology reported a 25% revenue increase for the first half of 2025, yet underlying profits slipped due to margin pressures from tariffs and product mix shifts. The launch of the A-Star Raptor dual screen cabinet bolstered Asia Pacific sales, while challenges persist in Latin America and online segments.

Ainsworth Game Technology reported a steady profit before tax of $13.9 million for the first half of 2025, supported by a 25% revenue increase driven by strong North American and Asia Pacific markets.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

Audinate Group Limited reported a 32% revenue decline and a net loss in FY25 amid industry headwinds, while expanding gross margins and completing a strategic acquisition to boost its video capabilities.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.